219 related articles for article (PubMed ID: 37270847)
21. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.
Varghese AM; Patel J; Janjigian YY; Meng F; Selcuklu SD; Iyer G; Houck-Loomis B; Harding JJ; O'Reilly EM; Abou-Alfa GK; Lowery MA; Berger MF
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250419
[TBL] [Abstract][Full Text] [Related]
22. The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.
Spahn S; Kleinhenz F; Shevchenko E; Stahl A; Rasen Y; Geisler C; Ruhm K; Klaumuenzer M; Kronenberger T; Laufer SA; Sundberg-Malek H; Bui KC; Horger M; Biskup S; Schulze-Osthoff K; Templin M; Malek NP; Poso A; Bitzer M
Nat Commun; 2024 Feb; 15(1):1287. PubMed ID: 38346946
[TBL] [Abstract][Full Text] [Related]
23. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
Katoh M; Loriot Y; Brandi G; Tavolari S; Wainberg ZA; Katoh M
Nat Rev Clin Oncol; 2024 Apr; 21(4):312-329. PubMed ID: 38424198
[TBL] [Abstract][Full Text] [Related]
24. FGF10/FGFR2 Signaling: Therapeutically Targetable Vulnerability in Ligand-responsive Cholangiocarcinoma Cells.
Oeurn K; Jusakul A; Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Kongpetch S
In Vivo; 2023; 37(4):1628-1637. PubMed ID: 37369494
[TBL] [Abstract][Full Text] [Related]
25. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
26. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
28. Targeting FGFR inhibition in cholangiocarcinoma.
Goyal L; Kongpetch S; Crolley VE; Bridgewater J
Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
[TBL] [Abstract][Full Text] [Related]
29. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
30. FGFR2 Inhibition in Cholangiocarcinoma.
Vogel A; Segatto O; Stenzinger A; Saborowski A
Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
[TBL] [Abstract][Full Text] [Related]
31. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Krook MA; Bonneville R; Chen HZ; Reeser JW; Wing MR; Martin DM; Smith AM; Dao T; Samorodnitsky E; Paruchuri A; Miya J; Baker KR; Yu L; Timmers C; Dittmar K; Freud AG; Allenby P; Roychowdhury S
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371345
[TBL] [Abstract][Full Text] [Related]
32. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
[TBL] [Abstract][Full Text] [Related]
33. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
34. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
35.
Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models.
Chew NJ; Lim Kam Sian TCC; Nguyen EV; Shin SY; Yang J; Hui MN; Deng N; McLean CA; Welm AL; Lim E; Gregory P; Nottle T; Lang T; Vereker M; Richardson G; Kerr G; Micati D; Jardé T; Abud HE; Lee RS; Swarbrick A; Daly RJ
Breast Cancer Res; 2021 Aug; 23(1):82. PubMed ID: 34344433
[TBL] [Abstract][Full Text] [Related]
37. Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.
Lamarca A; Ostios L; McNamara MG; Garzon C; Gleeson JP; Edeline J; Herrero A; Hubner RA; Moreno V; Valle JW
Cancer Treat Rev; 2023 Dec; 121():102627. PubMed ID: 37925878
[TBL] [Abstract][Full Text] [Related]
38. Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies.
Brandi G; Relli V; Deserti M; Palloni A; Indio V; Astolfi A; Serravalle S; Mattiaccio A; Vasuri F; Malvi D; Deiana C; Pantaleo MA; Cescon M; Rizzo A; Katoh M; Tavolari S
Sci Rep; 2024 Feb; 14(1):3136. PubMed ID: 38326380
[TBL] [Abstract][Full Text] [Related]
39. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
40. Outcomes following FGFR Inhibitor Therapy in Patients with Cholangiocarcinoma.
Gile JJ; Wookey V; Zemla TJ; Shi Q; Jin Z; Alberts SR; McWilliams RR; Ma WW; Borad M; Bekaii-Saab TS; Tran NH; Mahipal A
Target Oncol; 2022 Sep; 17(5):529-538. PubMed ID: 36056231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]